Eur Rev Med Pharmacol Sci 2016; 20 (8): 1516-1520

Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer

L.-L. Jing, X.-M. Mo

Laboratory of Stem Cell Biology and Department of Pediatric Surgery, State Key Laboratory of Biotherapy and Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

OBJECTIVE: The present study was designed to explore expression and prognostic value of miR-485-5p in patients with gastric cancer.

PATIENTS AND METHODS: We determined the expression level of miR-485-5p in 132 cases of paired GC and adjacent non-tumor tissues by quantitative real-time PCR (qRT-PCR). The relevance of miR-485-5p expression to the clinicopathological factors was assessed. Overall survival (OS) was examined using Kaplan-Meier curves and the Cox proportional hazards regression model.

RESULTS: The expression of miR-485-5p was significantly down-regulated in GC tissues compared with adja­cent normal tissues (p < 0.01). MiR-485-5p expression was positively correlated with larger tumor size (p = 0.003), deeper invasion depth, (p = 0.005), positive lymph node metastasis (p = 0.039), advanced tumor-node-metastasis (TNM) stage (p = 0.017). Patients survival analysis showed that a clear positive correlation between miR-485-5p expression level and survival time of gastric cancer patients (p < 0.001). Multivariate analyses confirmed that a low level of miR-485-5p expression was an independent predictor of poor prognosis in GC patients.

CONCLUSIONS: Expression level of miR-485-5p serves as a novel biomarker for the overall survival of patients with gastric cancer.

Free PDF Download

To cite this article

L.-L. Jing, X.-M. Mo
Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 8
Pages: 1516-1520